OBJECTIVE: To determine risk factor for non-AIDS severe clinical events in HIV-infected patients on long-term combination antiretroviral therapy (cART). METHODS: A validation committee reviewed each severe clinical event that occurred in the APROCO/COPILOTE (ANRS CO8) cohort that enrolled 1281 patients in 1997-1999 at the initiation of cART containing protease inhibitor. Probability of the occurrence of a first non-AIDS, cART-related, and AIDS-defining event was estimated, and potential determinants were studied using Cox regression models. RESULTS: During a median follow-up of 7.3 years, the incidence of non-AIDS events was higher than that of cART-related and AIDS-defining events (10.5, 3.6, and 2.6 per 100 patient-years, respectively). Bacterial (mainly airway) infections were the most frequent non-AIDS events (23.4%) followed by non-AIDS-defining malignancies and cardiovascular events (both 9.5%). Factors independently associated with the occurrence of a first non-AIDS event were age >60 years [hazard ratio (HR) 2.1; 95% confidence interval (CI): 1.3 to 3.2] and CD4 <100 cells per milliliter (HR 2.5; 95% CI: 1.8 to 3.6) but also plasma HIV RNA >4 log10 copies per milliliter at the time of the event (HR 1.9; 95% CI: 1.5 to 2.5). CONCLUSION: Optimization and permanent continuation of long-term antiretroviral therapy in HIV-infected patients is the best strategy to prevent or reduce the occurrence of non-AIDS severe morbidity.
OBJECTIVE: To determine risk factor for non-AIDS severe clinical events in HIV-infectedpatients on long-term combination antiretroviral therapy (cART). METHODS: A validation committee reviewed each severe clinical event that occurred in the APROCO/COPILOTE (ANRS CO8) cohort that enrolled 1281 patients in 1997-1999 at the initiation of cART containing protease inhibitor. Probability of the occurrence of a first non-AIDS, cART-related, and AIDS-defining event was estimated, and potential determinants were studied using Cox regression models. RESULTS: During a median follow-up of 7.3 years, the incidence of non-AIDS events was higher than that of cART-related and AIDS-defining events (10.5, 3.6, and 2.6 per 100 patient-years, respectively). Bacterial (mainly airway) infections were the most frequent non-AIDS events (23.4%) followed by non-AIDS-defining malignancies and cardiovascular events (both 9.5%). Factors independently associated with the occurrence of a first non-AIDS event were age >60 years [hazard ratio (HR) 2.1; 95% confidence interval (CI): 1.3 to 3.2] and CD4 <100 cells per milliliter (HR 2.5; 95% CI: 1.8 to 3.6) but also plasma HIV RNA >4 log10 copies per milliliter at the time of the event (HR 1.9; 95% CI: 1.5 to 2.5). CONCLUSION: Optimization and permanent continuation of long-term antiretroviral therapy in HIV-infectedpatients is the best strategy to prevent or reduce the occurrence of non-AIDS severe morbidity.
Authors: Benjamin N Breyer; Stephen K Van den Eeden; Michael A Horberg; Michael L Eisenberg; Donna Y Deng; James F Smith; Alan W Shindel Journal: J Urol Date: 2011-03-21 Impact factor: 7.450
Authors: Pragna Patel; Charles E Rose; Pamela Y Collins; Bernardo Nuche-Berenguer; Vikrant V Sahasrabuddhe; Emmanuel Peprah; Susan Vorkoper; Sonak D Pastakia; Dianne Rausch; Naomi S Levitt Journal: AIDS Date: 2018-07-01 Impact factor: 4.177
Authors: Nicolas Dauby; Stéphane De Wit; Marc Delforge; Valentina Coca Necsoi; Nathan Clumeck Journal: J Int AIDS Soc Date: 2011-03-28 Impact factor: 5.396
Authors: Constanza Lucero; Berta Torres; Agathe León; Marta Calvo; Lorna Leal; Iñaki Pérez; Montserrat Plana; Mireia Arnedo; Josep Mallolas; Josep M Gatell; Felipe García Journal: AIDS Res Hum Retroviruses Date: 2013-04-18 Impact factor: 2.205
Authors: Christopher J Hoffmann; Michael Schomaker; Matthew P Fox; Portia Mutevedzi; Janet Giddy; Hans Prozesky; Robin Wood; Daniela B Garone; Matthias Egger; Andrew Boulle Journal: J Acquir Immune Defic Syndr Date: 2013-05-01 Impact factor: 3.731